Rino Rappuoli is Head of Research and Development and Chief Scientist of GSK Vaccines globally and CEO of GSK Vaccines in Siena. He is the scientific coordinator of the MAD Lab at Toscana Life Sciences , and Professor of Vaccines Research, Imperial College, London.
Prior positions were: head of Vaccine R&D at Novartis, CSO of Chiron Corporation, and head for R&D at Sclavo. He earned his PhD in Biological Sciences at the University of Siena, Italy, and was visiting scientist at Rockefeller University and Harvard Medical School.
He is elected member of US National Academy of Sciences (NAS), the European Molecular Biology Organization (EMBO), and the Royal Society of London. Awards received include: the Paul Ehrlich and Ludwig Darmstaedter Prize, the Gold Medal by the Italian President, the Albert B Sabin Gold Medal, the Canada Gairdner International Award, and the European Inventor Award for Lifetime Achievement. He was nominated third most influential person worldwide in the field of vaccines (Terrapin). He has published more than 745 works in peer-reviewed journals.
He introduced novel scientific concepts: genetic detoxification; cellular microbiology; reverse vaccinology; pangenome. Developed licensed vaccines: acellular pertussis containing a non-toxic mutant of pertussis toxin; the first conjugate vaccine against meningococcus C; MF59, the first vaccine adjuvant after aluminium salts; meningococcus B; CRM197 that is used as carrier in many conjugate vaccines.
In 2020 he received an honorary degree from the University of Wurzburg, the Gentile Award from Fabriano, and the Pegaso d'Oro from the Tuscany Region. In 2021 he was named Cavaliere del Lavoro. Dr. Rappuoli is among the world scientific leaders dedicated to the sustainability of global health.